The Molecular Mechanism of Resistance of TKI After TKI

Up to 50 percent even 60-70 percent of these resistant tumors depend on a new ALQ mutation when you use sariqinib by likeinib regachinib or HACIN. The main paradigm not to forget we know it from each year far is what to do in any type of resistance if you have I would say an oligo progression so a progression which can be counted one two new lesion, one or two lymph nodes something which is tiny but objectively progressing.